Cancer Treatment Centers of America Selects WIRB-Copernicus Group

Article

Applied Clinical Trials

WIRB-Copernicus Group announced that it has been chosen by Cancer Treatment Centers of America to expand its clinical research program.

 

WIRB-Copernicus Group (WCG), a global provider of regulatory and ethical review services and software to support clinical research, announced that it has been chosen by Cancer Treatment Centers of America® (CTCA) to expand its clinical research program. WCG will assist CTCA in the centralization and optimization of its regulatory and ethical review process, allowing CTCA to manage a higher volume of cutting-edge research while maintaining participant protection. CTCA is a leader in integrative cancer care with a national network of five state-of-the-art hospitals in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa.WCG was chosen for its experience in reviewing oncology research, and WCG Oncology™, WCG’s oncology-focused oversight division, will partner with CTCA in its expansion process. 

 

Read the full release here.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.